View Cart  

Investigation of Abiomed Marketing Practices Shadows Strong Quarter

Cardiac devicemaker Abiomed is under scrutiny for its marketing and labeling of the Impella 2.5 heart pump, the company said in a Nov. 1 earnings statement covering the second quarter of fiscal 2013.

To View This Article:


Subscribe To Devices & Diagnostics Letter

Buy This Article Now

Add this article to your cart for $25.00